Raymond James Financial Inc. Takes $554,000 Position in Achieve Life Sciences, Inc. (NASDAQ:ACHV)

Raymond James Financial Inc. bought a new stake in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 157,519 shares of the biopharmaceutical company's stock, valued at approximately $554,000. Raymond James Financial Inc. owned 0.46% of Achieve Life Sciences at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Sigma Planning Corp bought a new position in Achieve Life Sciences in the fourth quarter worth about $37,000. ADAR1 Capital Management LLC boosted its position in Achieve Life Sciences by 14,375.8% in the fourth quarter. ADAR1 Capital Management LLC now owns 13,173 shares of the biopharmaceutical company's stock valued at $46,000 after buying an additional 13,082 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in Achieve Life Sciences in the fourth quarter valued at approximately $49,000. Intech Investment Management LLC purchased a new stake in Achieve Life Sciences in the 4th quarter worth approximately $58,000. Finally, SG Americas Securities LLC boosted its position in Achieve Life Sciences by 74.8% in the 4th quarter. SG Americas Securities LLC now owns 19,886 shares of the biopharmaceutical company's stock worth $70,000 after purchasing an additional 8,512 shares in the last quarter. 33.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Achieve Life Sciences

In other news, CFO Mark K. Oki purchased 10,000 shares of the business's stock in a transaction on Monday, March 17th. The shares were bought at an average price of $2.89 per share, with a total value of $28,900.00. Following the completion of the transaction, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $28,900. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.00% of the stock is currently owned by company insiders.

Achieve Life Sciences Price Performance

Shares of NASDAQ:ACHV traded up $0.13 during midday trading on Monday, reaching $2.48. 125,126 shares of the company's stock traded hands, compared to its average volume of 188,361. Achieve Life Sciences, Inc. has a 1 year low of $1.84 and a 1 year high of $5.59. The company has a market cap of $86.02 million, a P/E ratio of -2.19 and a beta of 1.49. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.78 and a current ratio of 6.78. The company has a fifty day simple moving average of $2.51 and a two-hundred day simple moving average of $3.36.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last issued its earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.06). Equities analysts predict that Achieve Life Sciences, Inc. will post -1.17 EPS for the current fiscal year.

Achieve Life Sciences Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.